Ocular Therapeutix, Inc. has announced its participation in the Angiogenesis ... and its application in treating retinal diseases. Notable presentations include the results from the Phase 1 ...
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...
Retinal neovascularization (from diabetes mellitus, retinopathy of prematurity and age-related macular degeneration) is the most common cause of blindness 1,2. The present treatment, laser ...
The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
Alpharetta, Georgia Wednesday, February 12, 2025, 16:30 Hrs [IST] ...
“Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual ...
SubQ administered MGB selectively targets and reduces fluid production in the retina of both eyes to ... were presented at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting ...
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback